Effect of ticagrelor and clopidogrel on inflammatory factors in patients with coronary heart disease after percutaneous coronary intervention operation
10.13699/j.cnki.1001-6821.2016.14.003
- VernacularTitle:替格瑞洛与氯吡格雷对冠心病患者冠状动脉介入术后炎症因子的影响
- Author:
Yong ZHU
1
;
Mei-Chun ZHANG
;
Meng-Qiu GAO
;
Yan-Xia SUN
;
Jun-Ling HU
;
Cheng-Long HE
;
Chong-Hui WANG
;
Yu-Ming LI
Author Information
1. 天津医科大学研究生院
- Keywords:
ticagrelor;
clopidogrel;
coronary heart disease;
percutaneous coronary intervention
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(14):1257-1260
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compared the influence on inflammatory factors of using ticagrelor and clopidogrel in patients with coronary heart disease after percutaneous coronary intervention ( PCI ) operation . Methods A total of 110 patients with coronary heart disease after PCI were divided into treatment group and control group ,55 cases in each group.Treatment group was given ticagrelor 90 mg, qd, and control group given clopidogrel 300 mg, qd.The course of two groups were both one month .The throm-bolysis in myocardial infarction ( TIMI ) blood flow and no reflow incidence of two groups were compared after treat-ment.Inflammatory factor C-reactive protein (CRP), interleukin 6 (IL-6), myelo peroxidase(MPO), and soluble CD40 receptor (sCD40L) levels were compared of the two groups before surgery and 1 week, 1, 3 and 6 months after treatment.The incidence of major cardiovascular adverse events was compared of two groups .Results There was no reflow case found in treatment group , and two cases of no reflow were founded in control group (3.64%, P>0.05 ). The number of patients in TIMI level 3 of treatment group and control group were 53 ( 96.36%) and 44 ( 88.00%, P<0.05).The levels of CRP, IL -6, MPO, sCD40L in one week of treatment group were ( 12.05 ±1.06 ) ng? mL-1 ,(3.38 ±0.83 ) pg? mL-1 , ( 233.16 ±25.24 )μg? mL-1 , ( 632.38 ±24.99 ) pg? mL-1 , and were (10.37 ±1.88 ) ng? mL-1 ,(7.96 ±0.99 ) pg? mL-1 ,(237.06 ±20.33 )μg? mL-1 ,(624.46 ±22.33 ) pg? mL-1 in control group(P<0.05).The levels of CRP, IL-6, MPO, sCD40L in one month of treatment group were (4.68 ± 1.38)ng? mL-1,(3.13 ±1.11)pg? mL-1,(204.49 ±21.38)μg? mL-1,(588.67 ±19.55)pg? mL-1, and were (3.04 ±1.17)ng? mL-1,(2.15 ±1.29)pg? mL-1,(179.06 ±20.29)μg? mL-1,(565.27 ±21.15)pg? mL-1in control group(P<0.05).The levels of CRP, IL-6, MPO, sCD40L in three months of treatment group were (4.26 ± 0.53)ng? mL-1,(3.07 ±1.09)pg? mL-1,(198.11 ±21.25)μg? mL-1,(574.17 ±26.31)pg? mL-1, and were (2.92 ±0.97)ng? mL-1,(2.12 ±1.34)pg? mL-1,(165.19 ±25.63)μg? mL-1,(522.17 ±23.42)pg? mL-1in control group(P<0.05).The levels of CRP, IL-6, MPO, sCD40L in six months were (4.14 ±0.49)ng? mL-1, (3.05 ±1.13)pg? mL-1,(200.16 ±22.17)μg? mL-1,(363.26 ±19.48)pg? mL-1 in treatment group, and were (2.79 ±1.11)ng? mL-1,(2.08 ±1.32)pg? mL -1,(174.06 ±22.01)μg? mL-1,(323.55 ±24.63)pg? mL-1 in control group ( P <0.05 ) .The adverse reactions mainly manifested as cardiac death , atrial fibrillation , recurrent myocardial infarction , the incidence of major cardiovascular adverse events in treatment group ( 9.09%) was signifi-cantly higher than that in control group ( 7.27%, P>0.05 ) .Conclusion Ticagrelor effectively reduce the level of inflammatory reaction in patients with coronary heart disease after PCI , improve the prognosis and reduce the incidence of adverse reactions.
